ViiV Healthcare

Pharmaceutical companies GSK and Servier have agreed at the St. Petersburg International Economic Forum to increase production of a medicine for the treatment of HIV infection at the Servier RUS factory in Moscow, press office of the Department of Investment and Industrial Policy of Moscow announced on Wednesday.

02 June 2021

The production of the Dolutegravir preparation which was developed by ViiV Healthcare to treat HIV will be localized in Russia. The drug will be produced by the Moscow-based Servier pharmaceutical plant.

24 August 2017

Serdix of Russia started its integrated production of the first registration series of Tivicay® (INN Dolutegravir) by ViiV Healthcare within the framework of the partnership agreement for localization of production of the drug for HIV infected in Russia.

The Project Launch Memorandum was executed on 25 May 2016 within the framework of the annual forum hosted by the Science, Industrial Policy and Entrepreneurship Department of the Moscow Government with the capital city Mayor, Mr. Sergei Sobyanin, in attendance.

01 September 2016

British company ViiV Healthcare announced its intention to localize a drug for the treatment of human immunodeficiency virus (HIV) - Dolutegravir (active ingredient) in Russia. According to the representatives of both parties, the production will be launched at the facilities of Serdix, Russian subsidiary of French company Servier.

30 May 2016
3.7 mln
Moscow Region

Investor profile

ViiV Healthcare

Great Britain

Company's website:

T: +44 (0)20 8380 6200

Private company

Contact: Dr Dominique Limet, Director General

ViiV Healthcare was established in 2009 and is an international company specializing in the treatment of HIV infections; the majority interest is owned by GSK, other two shareholders are Pfizer and Shionogi.